Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Evofem Biosciences, Inc. (NASDAQ: EVFM).

Full DD Report for EVFM

You must become a subscriber to view this report.


Recent News from (NASDAQ: EVFM)

Your Daily Pharma Scoop: Karyopharm Buoyed, MediNova Succeeds, Ardelyx's Publication
Stocks in the News Karyopharm up 4% ahead of presentation of selinexor data Discussion Karyopharm Therapeutics ( KPTI ) reported that they plan to present, at the Society of Hematologic Oncology ((SOHO)) Annual Meeting in Houston, data from their Phase 2b STORM study evaluating sel...
Source: SeekingAlpha
Date: August, 31 2018 12:18
Midday Gainers / Losers (08/29/2018)
Gainers: OPNT +50% . IGC +40% . GKOS +36% . EVFM +26% . IPAS +27% . SPHS +27% . AFMD +25% . JMU +19% . YRD +17% . ZYNE +17% . More news on: Opiant Pharmaceuticals, Inc., India Globalization Capital, Inc, Glaukos, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 29 2018 12:48
Evofem advancing Amphora gel for prevention of certain STDs in women; shares ahead 15%
Thinly traded nano cap Evofem Biosciences ( EVFM +14.5% ) is up on a 4x surge in volume, albeit on turnover of only 259K shares. The stock has rallied over  60%  since touching $1.83 on August 8. More news on: Evofem Biosciences, Inc., Healthcare stocks news, Stocks on the move...
Source: SeekingAlpha
Date: August, 29 2018 11:42
Rise in Prevalence of STDs Reported by CDC Supports Continued Development of Novel Solutions, Like Evofem's Product in Development, Amphora®, for the Prevention of Chlamydia
SAN DIEGO , Aug. 29, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health,...
Source: PR Newswire
Date: August, 29 2018 09:00
Evofem Biosciences to Present at 20th Annual Global Investment Conference on September 6, 2018
SAN DIEGO , Aug. 23, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health,...
Source: PR Newswire
Date: August, 23 2018 09:00
Evofem Biosciences' Chief Medical Officer, Dr. Kelly Culwell, to Present at #BlogHer18 Creators Summit
SAN DIEGO , Aug. 7, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem"), announced today that its Chief Medical Officer, Kelly Culwell, MD, will present at the #BlogHer18 Creators Summit, presented by SheKnows Media, on Wednesday, August 8, 2018 at 4:05 p...
Source: PR Newswire
Date: August, 07 2018 09:00
Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q2 2018 Results - Earnings Call Transcript
Evofem Biosciences, Inc. (EVFM) Q2 2018 Results Earnings Conference Call August 02, 2018 11:00 AM ET Executives Amy Raskopf - Investor Relations Saundra Pelletier - Chief Executive Officer Jay File - Chief Financial Officer Russ Barrans - Chief Commercial Officer Dr. Kelly Cu...
Source: SeekingAlpha
Date: August, 06 2018 16:10
Premarket Gainers as of 9:05 am (08/03/2018)
WMLP +179% . More news on: Westmoreland Resource Partners, LP, Sierra Wireless, Inc., Acacia Communications, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 03 2018 09:16
Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update
SAN DIEGO , Aug. 2, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, today...
Source: PR Newswire
Date: August, 02 2018 06:50
Upcoming 3% To 4% Book Value Growth For This 9.2% Yielding BDC Positioned For Rising Rates
Q2 2018 BDC Reporting Business development companies ("BDCs") will be reporting June 30, 2018, results this weeks including Hercules Capital ( HTGC ) and I will likely be making changes to my personal portfolio. My recent articles on THL Credit ( TCRD ), Ares Capital ( ARCC ), and M...
Source: SeekingAlpha
Date: July, 29 2018 10:32

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-084.444.704.934.3201339,955
2018-05-175.285.235.445.0122,851

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-119,95711,62385.6664Short
2018-12-101,7142,01285.1889Short
2018-12-071,2202,40850.6645Short
2018-12-063,02117,24317.5202Cover
2018-12-047,21517,47541.2876Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EVFM.


About Evofem Biosciences, Inc. (NASDAQ: EVFM)

Logo for Evofem Biosciences, Inc. (NASDAQ: EVFM)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $13,088,764 - 05/15/2018
    • Issue and Outstanding: 2,308,424 - 01/18/2018

     


    Recent Filings from (NASDAQ: EVFM)

    Withdrawal of registration statement filed under the Securities Act
    Filing Type: RWFiling Source: edgar
    Filing Date: May, 16 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 16 2018
    General form for registration of securities under the Securities Act of 1933
    Filing Type: S-1Filing Source: edgar
    Filing Date: May, 16 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 14 2018
    Free Writing Prospectus
    Filing Type: FWPFiling Source: edgar
    Filing Date: May, 09 2018
    Free Writing Prospectus
    Filing Type: FWPFiling Source: edgar
    Filing Date: May, 09 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 08 2018
    Amendment to general form for registration of securities under the Securities Act of 1933
    Filing Type: S-1/AFiling Source: edgar
    Filing Date: May, 01 2018
    Amendment to general form for registration of securities under the Securities Act of 1933
    Filing Type: S-1/AFiling Source: edgar
    Filing Date: April, 24 2018
    Amendment to a previously filed 8-K
    Filing Type: 8-K/AFiling Source: edgar
    Filing Date: April, 06 2018

     

     


    Daily Technical Chart for (NASDAQ: EVFM)

    Daily Technical Chart for (NASDAQ: EVFM)


    Stay tuned for daily updates and more on (NASDAQ: EVFM)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: EVFM)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EVFM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of EVFM and does not buy, sell, or trade any shares of EVFM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/